BioWorld

June 25, 2008

Microbix Brokers Deal for Flu Manufacturing Facility in China

After a year of negotiations, Toronto-based Microbix Biosystems Inc. signed a definitive agreement with the Hunan Provincial Government for the construction of a $200 million flu vaccine manufacturing facility. (BioWorld Today) Read More

Congress Urged to Create Incentives for Antimicrobials

Averages Can Mask Real Gene Methylation Changes

NewCo News: ACT's Business Model Aims for Steady Stream of Cancer Drugs

Sirion's Durezol Wins Approval in Ocular Inflammation, Pain

RXi Follows Public Listing with $8.7M Private Placement

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...